Trial Profile
A Multicentre, Randomised, Open-label, Parallel-Group Pilot Study to Evaluate the Efficacy of Patiromer in Optimising Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Subjects with Hyperkalaemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms CONTINUE-HF
- Sponsors Fresenius Medical Care
- 17 Jan 2020 Status changed from recruiting to completed.
- 02 Jan 2018 New trial record